SCHEMBL16822326

SCHEMBL16822326

O=C(O)n1cnc2cc(F)ccc21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
GFER P55789 1/20 0.49
THRB P10828 1/20 0.40
FGFR1 P11362 3/20 0.39
HCAR3 P49019 1/20 0.39
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TBXA2R P21731 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KCNMA1 Q12791 1/20 0.38
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
MAPK10 P53779 1/20 0.37
ASAH1 Q13510 1/20 0.37
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30204372 0.86 KMT2A (0.49) KMT2AGFERFGFR1TBXA2RSMN1; SMN2
SCHEMBL19848406 0.85 KMT2A (0.51) KMT2AGFERTHRBFGFR1HCAR3
SCHEMBL19911432 0.82 KMT2A (0.46) KMT2AGFERTHRBFGFR1HSD17B10
SCHEMBL19716710 0.79 FGFR1 (0.53) KMT2AGFERFGFR1HCAR3HPGD
SCHEMBL28227235 0.79 FGFR1 (0.60) THRBFGFR1HCAR3HSD17B10ALDH1A1
SCHEMBL482160 0.79 SIK1 (0.45) KMT2AGFERFGFR1HCAR3HSD17B10
SCHEMBL31450450 0.79 GGPS1 (0.45) KMT2AGFERTHRBFGFR1HCAR3
SCHEMBL24110391 0.77 GFER (0.45) KMT2AGFERALDH1A1HPGDSMN1; SMN2
SCHEMBL19717080 0.76 ASAH1 (0.40) KMT2AGFERFGFR1HCAR3HSD17B10
SCHEMBL4552025 0.75 KMT2A (0.40) KMT2AGFERTHRBHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219460-B1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA INC (US) 2025-02-26 EP claimed
US-10195195-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2019-02-05 US disclosed
EP-3378476-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS Sensorion (FR) 2018-09-26 EP disclosed
US-9688989-B2 H4 receptor inhibitors for treating tinnitus SENSORION (FR) 2017-06-27 US disclosed
US-20170056397-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-03-02 US disclosed
EP-3130376-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-02-15 EP disclosed
US-9526725-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2016-12-27 US disclosed
US-20150176010-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS SENSORION (FR) 2015-06-25 US disclosed